Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
2457 | 2170 | 51.4 | 94% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
295 | 18105 | FANCONI ANEMIA//ATAXIA TELANGIECTASIA//WERNER SYNDROME |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | CHK1 | Author keyword | 181 | 56% | 10% | 220 |
2 | RAD9 | Author keyword | 53 | 69% | 2% | 45 |
3 | CLASPIN | Author keyword | 44 | 78% | 1% | 29 |
4 | CHECKPOINT | Author keyword | 41 | 21% | 8% | 172 |
5 | HUS1 | Author keyword | 30 | 84% | 1% | 16 |
6 | CHECKPOINT KINASE 1 | Author keyword | 29 | 67% | 1% | 26 |
7 | RAD17 | Author keyword | 25 | 77% | 1% | 17 |
8 | CHK2 | Author keyword | 24 | 30% | 3% | 67 |
9 | RAD53 | Author keyword | 23 | 51% | 2% | 33 |
10 | TOPBP1 | Author keyword | 23 | 59% | 1% | 26 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | CHK1 | 181 | 56% | 10% | 220 | Search CHK1 | Search CHK1 |
2 | RAD9 | 53 | 69% | 2% | 45 | Search RAD9 | Search RAD9 |
3 | CLASPIN | 44 | 78% | 1% | 29 | Search CLASPIN | Search CLASPIN |
4 | CHECKPOINT | 41 | 21% | 8% | 172 | Search CHECKPOINT | Search CHECKPOINT |
5 | HUS1 | 30 | 84% | 1% | 16 | Search HUS1 | Search HUS1 |
6 | CHECKPOINT KINASE 1 | 29 | 67% | 1% | 26 | Search CHECKPOINT+KINASE+1 | Search CHECKPOINT+KINASE+1 |
7 | RAD17 | 25 | 77% | 1% | 17 | Search RAD17 | Search RAD17 |
8 | CHK2 | 24 | 30% | 3% | 67 | Search CHK2 | Search CHK2 |
9 | RAD53 | 23 | 51% | 2% | 33 | Search RAD53 | Search RAD53 |
10 | TOPBP1 | 23 | 59% | 1% | 26 | Search TOPBP1 | Search TOPBP1 |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | DNA DAMAGE CHECKPOINT | 220 | 36% | 23% | 489 |
2 | CHK1 | 166 | 50% | 11% | 237 |
3 | ATR | 79 | 31% | 10% | 212 |
4 | REPLICATION CHECKPOINT | 76 | 56% | 4% | 92 |
5 | S PHASE CHECKPOINT | 73 | 26% | 11% | 237 |
6 | DAMAGE CHECKPOINT | 59 | 35% | 6% | 137 |
7 | BUDDING YEAST RAD9 | 52 | 71% | 2% | 42 |
8 | REPEATED PHOSPHOPEPTIDE MOTIFS | 48 | 100% | 1% | 17 |
9 | MEC1 DEPENDENT PHOSPHORYLATION | 39 | 80% | 1% | 24 |
10 | CHECKPOINT KINASE 1 | 37 | 73% | 1% | 29 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
ATR: an essential regulator of genome integrity | 2008 | 654 | 179 | 53% |
Causes and consequences of replication stress | 2014 | 74 | 133 | 24% |
The ATM-Chk2 and ATR-Chk1 Pathways in DNA Damage Signaling and Cancer | 2010 | 253 | 192 | 52% |
CHEK again: Revisiting the development of CHK1 inhibitors for cancer therapy | 2014 | 14 | 94 | 76% |
Roles of Chk1 in cell biology and cancer therapy | 2014 | 15 | 189 | 68% |
Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints | 2004 | 1373 | 264 | 31% |
The DNA damage response: putting checkpoints in perspective | 2000 | 1843 | 92 | 49% |
Targeting ATR in DNA damage response and cancer therapeutics | 2014 | 14 | 122 | 57% |
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics | 2011 | 99 | 84 | 57% |
Anticancer therapy with checkpoint inhibitors: what, where and when? | 2011 | 57 | 57 | 88% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | GENOME DYNAM PROJECT | 3 | 22% | 0.5% | 11 |
2 | CELL CYCLE CANC | 2 | 27% | 0.4% | 8 |
3 | GENOM ABIL GRP | 2 | 21% | 0.5% | 10 |
4 | BIOACTS | 2 | 67% | 0.1% | 2 |
5 | GLOBAL INTEGRATED STUDIES | 2 | 67% | 0.1% | 2 |
6 | MED SVH | 2 | 50% | 0.1% | 3 |
7 | ENVIRONM HLTH SUSCEPTIBIL | 2 | 15% | 0.5% | 11 |
8 | CELL MUTAT UNIT | 1 | 12% | 0.6% | 12 |
9 | 47S 9A | 1 | 100% | 0.1% | 2 |
10 | 4MD 10 | 1 | 100% | 0.1% | 2 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000174756 | UCN 01//7 HYDROXYSTAUROSPORINE//7 HYDROXYSTAUROSPORINE UCN 01 |
2 | 0.0000165194 | NIJMEGEN BREAKAGE SYNDROME//53BP1//NBS1 |
3 | 0.0000097890 | GEMININ//DNA REPLICATION//CDC6 |
4 | 0.0000097067 | CDC25B//CDC25A//AUTOSCHIZIS |
5 | 0.0000083242 | REPLICATION PROTEIN A//SINGLE STRANDED DNA BINDING PROTEIN//REPLICATION PROTEIN A RPA |
6 | 0.0000082688 | ATAXIA TELANGIECTASIA//ATM GENE//ATAXIA TELEANGIECTASIA |
7 | 0.0000078875 | G2 REPAIR//CHROMATID TYPE ABERRATIONS//G2 M OVERRIDE |
8 | 0.0000077156 | REVERSINE//MITOTIC CATASTROPHE//WP 631 |
9 | 0.0000077002 | CHEK2//PALB2//SERV CIRUGIA GEN ESPECIALIDADES |
10 | 0.0000076016 | OLAPARIB//SYNTHETIC LETHALITY//PARP INHIBITOR |